vimarsana.com
  1. Home
  2. Live Updates
  3. Phil Nadeau Cowen - Breaking News

Page 2 - Phil Nadeau Cowen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript

NBIX earnings call for the period ending June 30, 2022.

District of columbiaUnited statesTodd tushlaAnupam rama jpmorganKevin charles gormanRaymond jamesSosei heptaresChris shibutaniYatin suneja guggenheimKyle ganoDanielle brill raymond jamesMyles minter william blairPhil nadeau cowenCarter gould barclaysLaura chicoPiper sandler

Myovant Sciences Ltd (MYOV) Q1 2022 Earnings Call Transcript

MYOV earnings call for the period ending June 30, 2022.

United kingdomSumitomo pharmaJuan camiloJuan camilo arjonaBrian skorneyLauren merendinoUneek mehraDave marekPhil nadeau cowenPhil nadeauMyovant sciences ltdEuropean commissionCompany analystMyovant scienceInternal revenue code section

Biogen (BIIB) Q2 2022 Earnings Call Transcript

BIIB earnings call for the period ending June 30, 2022.

United statesMichael henckeMike mcdonnellRobyn karnauskasCory kasimovEvan seigermanSalveen richter goldman sachsMike yeePriya singhalMarc goodmanJay olson oppenheimerMichael yeePhil nadeau cowenBrian abrahamsSalveen richterGeoff meacham

Myovant Sciences Ltd (MYOV) Q4 2021 Earnings Call Transcript

MYOV earnings call for the period ending March 31, 2022.

Lauren merendinoPhil nadeau cowenRoanna ruizSumitomo pharmaMadhu kumarJuan camiloJuan camilo ferreiraJuan camilo arjonaBrian skorneyUneek mehraDave marekPhil nadeauRob palermo goldman sachsGavin clark gartnerDeric josephBrian skorney baird

Vertex Pharmaceuticals (VRTX) Q1 2022 Earnings Call Transcript

VRTX earnings call for the period ending March 31, 2022.

Robyn karnauskasCory kasimovCharlie wagnerReshma kewalramaniEvan seigermanSalveen richter goldman sachsMichael partridgeMichael yeePhil nadeau cowenSalveen richterGeoff meachamLiisa baykoAmerica merrill lynchDavid altshulerBastiano sannaRobyn karnauskas truist

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.